An NIH workshop aimed at promoting the efficient development and regulation of gene therapies highlighted a crucial bottleneck for the field Tuesday, as policy members of the rare disease community raised substantial questions about how to value and pay for the therapies. With three gene therapies already approved in the U.S. and a growing queue of new ones in development, panelists painted a picture of financial and institutional innovation struggling to keep pace with medical innovation.